Arbidol-FT

General characteristics. Structure:

Active ingredient: 50 mg or 100 mg of arbidol of a hydrochloride (in the form of monohydrate hydrochloride arbidol).

Excipients: starch corn, povidone, magnesium stearate, cellulose microcrystallic.

Structure of a cover: gipromelloza, titanium dioxide (Е 171), macrogoal 400.

Antiviral means with preferential action against influenza viruses And yes In, a parainfluenza and some other causative agents of respiratory viral infections.

Pharmacological properties:

Pharmacodynamics. Arbidol specifically suppresses influenza viruses And yes In, a parainfluenza, and also a number of causative agents of acute respiratory viral infections (respiratory and syncytial viruses, rhinoviruses, rotaviruses, adenoviruses, coronaviruses). Drug affects early stages of a virus reproduction in the owner's cell. On the mechanism of antiviral action arbidol belongs to fusion inhibitors (fuziya) of a virus with a cell since interacts with hemagglutinin of a virus and interferes with merge of a lipidic viral envelope and cellular membranes of endosomes. Release of a virus nucleocapsid and the beginning in a cell of a transcription of a virus genome is as a result slowed down.

Arbidol has moderate immunomodulatory effect which is shown in increase in total quantity of T lymphocytes and T-helperov, stimulations of phagocytal function of neutrophils and induction of activity of natural killers. Stimulation of a phagocytal link of immunity provides increase in resistance of a macroorganism to an infection. Arbidol is capable to induce production of endogenous interferon. Drug does not render immunosupressiruyushchy effect on development of specific antibodies to respiratory viruses that favourably distinguishes it from the majority of the antiviral means which are applied to prevention and treatment of flu and a SARS. Arbidol has antioxidant activity that promotes neutralization of the toxins which are formed in the patient's organism. 

Use of drug prevents development of postgrippal complications, reduces the frequency of development of the complications connected with a viral infection and also exacerbations of chronic bacterial diseases.

The therapeutic effectiveness at viral infections is shown in decrease in expressiveness of the general intoxication and the clinical phenomena, reduction of duration of a disease, decrease in risk of development of complications.
Arbidol belongs to low-toxic drugs (LD50> of 4 g/kg) and does not make any negative impact on a human body at oral administration in the recommended doses.
Pharmacokinetics. Absorption and distribution: it is quickly absorbed and distributed on bodies and fabrics. The maximum concentration (Cmax) in a blood plasma at reception in a dose of 50 mg is reached in 1,2 hours, in a dose of 100 mg – in 1,5 hours.
Metabolism and removal: it is metabolized in a liver. The elimination half-life (T1/2) is equal 17 - 21 hours. About 40% are removed in not changed look, generally with bile (38,9%) and in insignificant quantity kidneys (0,12%). Within the first days 90% of the entered dose are removed.

Indications to use:

- prevention and complex therapy at adults and children of flu A and B, acute respiratory viral infections (including complicated by bronchitis, pneumonia).

Route of administration and doses:

Pill ARBIDOL-FT is taken inside before meal. Single doses for children aged from 3 up to 6 years make 50 mg, from 6 to 12 years - 100 mg, 12 years and for adults - 200 mg are more senior (2 tablets on 100 mg or 4 tablets on 50 mg).

For nonspecific prevention. At direct contact with sick flu and other SARS drug is recommended to children aged from 3 up to 6 years in a dose of 50 mg/days, from 6 to 12 years – 100 mg/days, 12 years and adult - 200 mg/days are more senior. Drug is accepted by 1 times/days. The course of prevention makes 10-14 days.

In the period of a flu epidemic and other SARS, for prevention of an exacerbation of chronic bronchitis and pneumonia drug is recommended to children aged from 3 up to 6 years in a dose of 50 mg/days, from 6 to 12 years – 100 mg/days, 12 years and adult - 200 mg/days are more senior. Drug is accepted by 2 times a week within 3 weeks.

For treatment. At flu and other SARS without complications drug is recommended to children aged from 3 up to 6 years on 50 mg, from 6 to 12 years – on 100 mg, 12 years and the adult – on 200 mg 4 times a day (each 6 h) are more senior. The course of treatment makes 5 days.

At flu and other SARS with development of complications (including bronchitis, pneumonia) the course of treatment makes about 5 weeks and consists of two cycles. Originally drug is recommended to children aged from 3 up to 6 years on 50 mg, from 6 to 12 years – on 100 mg), 12 years and the adult – on 200 mg 4 times a day (each 6 h) within 5 days (the first cycle) are more senior. In the subsequent drug is appointed in a single dose for the corresponding age for 4 weeks (the second cycle) once a week.

Features of use:

Pregnancy and lactation. Safety of use of drug during pregnancy is not proved. Special clinical trials were not conducted. During pregnancy it is not appointed to avoid a possible adverse effect on a fruit.

It is not found out whether drug with mother's milk is emitted. If treatment by drug ARBIDOL-FT is necessary for mother, then feeding of the child a breast is stopped.

Management of transport and mechanisms: There are no data on an adverse effect of arbidol on the speed of psychomotor reaction. He does not show the central neurotropic activity and can be applied in medical practice in the preventive purposes at almost healthy faces of various professions including requiring special attention and coordination of movements (drivers, drivers, operators, etc.).

Side effects:

ARBIDOL-FT in the recommended doses is well transferred by patients. Side effects are not revealed, at certain patients the individual intolerance came to light.

Interaction with other medicines:

At appointment with other medicines of negative effects it was not noted.

Contraindications:

Hypersensitivity to drug, children's age up to 3 years.

Overdose:

Messages were not provided.

Storage conditions:

To store in the place protected from light at a temperature not above +25 °C. To store in the place, unavailable to children. Period of validity 2 years.

Issue conditions:

Without recipe

Packaging:

Tablets, coated, on 50 mg and 100 mg in a blister strip packaging No. 10×1, No. 10×2 and in banks No. 20, each of which are placed together with a leaf insert for the consumer in a pack from a cardboard.